Reapplix

Reapplix

Every wound is personal

Founded 2008 Denmark

Denmark 29 employees Series A Total: $181.10M Biotechnology, Health and Wellness +1

Reapplix, with the slogan "Every wound is personal," was founded in 2008 and is a leader in the biological treatment and management of diabetic foot ulcers. The company's innovative and patented 3C Patch® System leverages the individual patient’s capacity to heal and has been clinically proven to accelerate wound healing of chronic diabetic foot ulcers. Reapplix, headquartered in Denmark, has sales and distribution teams in the US and Europe. Notably, the company was the recipient of the Danish 2018 EY Entrepreneur of the Year Award in the life science category. Reapplix's last investment of kr150.00M in Series A occurred on 13 July 2020 and was backed by notable investors including Novo Holdings, VF Venture, Lauxera Capital Partners, and North-East Healthcare Investment. Reapplix's business model is underpinned by high-quality RCT evidence published in The Lancet in September 2018 and a 2019 IWGDF Recommendation. The company's mission revolves around "Drawing on the person’s power to heal so they can get back to living their best life,”, emphasizing a patient-centric approach to healthcare. For further information, visit www.reapplix.com.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	kr150.00M	4	Novo Holdings, VF Venture +2	13 Jul 2020
Venture Round	kr25.00M	3	Novo Holdings, Seed Capital +1	10 Oct 2019
Venture Round	€2.70M	3	Novo Holdings, Seed Capital +1	27 Sep 2016
Seed Round	$380.00K	1	Accelerace	04 Mar 2011
Seed Round	€1.02M	2	PreSeed Ventures, Seed Capital	03 Sep 2010
Seed Round	kr2.00M	1	Accelerace	09 Mar 2009

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

kr150.00M

Novo Holdings, VF Venture +2

13 Jul 2020

Venture Round

kr25.00M

Novo Holdings, Seed Capital +1

10 Oct 2019

Venture Round

€2.70M

Novo Holdings, Seed Capital +1

27 Sep 2016

Seed Round

$380.00K

Accelerace

04 Mar 2011

Seed Round

€1.02M

PreSeed Ventures, Seed Capital

03 Sep 2010

Seed Round

kr2.00M

Accelerace

09 Mar 2009

FAQ About Reapplix

Every wound is personal

Reapplix was founded in 2008.

Reapplix is headquartered in Denmark.

Reapplix operates in Biotechnology, Health and Wellness and Medical Devices. Its work centres on biological treatment, wound management, diabetic foot ulcers and innovative medical device.

Reapplix has approximately 29 employees.

Reapplix has completed 6 funding rounds, raising a total of $181.10M. The latest funding stage is Series A.

Top alternatives and competitors to Reapplix include Piomic Medical, SANUWAVE, RedDress Ltd., Fibralign Corporation, Regenesis. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Reapplix and Piomic Medical are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Reapplix

Funding Rounds & Investors (6)

Reapplix Alternatives & Competitors

FAQ About Reapplix